O
VIGL

OrbiMed’s Vigil Neuroscience VIGL Stock Holding History

OrbiMed’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-448,891
Closed -$1.53M – 140
2024
Q3 		$1.53M Hold
448,891
– – 0.03% 114
2024
Q2 		$1.8M Hold
448,891
– – 0.04% 108
2024
Q1 		$1.53M Hold
448,891
– – 0.03% 107
2023
Q4 		$1.52M Hold
448,891
– – 0.03% 101
2023
Q3 		$2.42M Hold
448,891
– – 0.05% 109
2023
Q2 		$4.22M Hold
448,891
– – 0.08% 106
2023
Q1 		$4.39M Hold
448,891
– – 0.09% 105
2022
Q4 		$5.61M Buy
448,891
+37,700
+9% +$463K 0.11% 92
2022
Q3 		$3.74K Hold
411,191
– – 0.07% 110
2022
Q2 		$1.06K Hold
411,191
– – 0.02% 140
2022
Q1 		$2.89M Buy
+411,191
New +$5.43M 0.05% 128

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

OrbiMed's VIGL Position: Q4 2024 in Review

OrbiMed sold out of Vigil Neuroscience (VIGL) in Q4 2024, closing a stake of 448,891 shares — an estimated $1.53M sold.

OrbiMed first reported a position in VIGL in Q1 2022 and held it in 11 quarters. The position peaked at $5.61M in Q4 2022. 51 funds tracked by Wall St. Rank hold VIGL as of Q4 2024.

  • OrbiMed reported no remaining Vigil Neuroscience position as of Q4 2024 after selling out during the quarter.
  • OrbiMed sold 448,891 Vigil Neuroscience shares in Q4 2024, an estimated $1.53M.
  • OrbiMed first reported a position in Vigil Neuroscience in Q1 2022 and held it in 11 quarters.
  • OrbiMed's Vigil Neuroscience position peaked at $5.61M in Q4 2022.
  • 51 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.